| 26.07 08:46 | dpa-AFX: European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis |
| 26.07 08:05 | dpa-AFX: *ABBVIE : EC OKS SKYRIZI FOR TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS |
| 25.07 22:13 | MÄRKTE USA/Uneinheitlich nach Vortageseinbruch - Ford unter Druck |
| 25.07 18:15 | MÄRKTE USA/Börsen nach Vortageseinbruch mit Aufschlägen - Ford unter Druck |
| 25.07 14:00 | dpa-AFX: AbbVie Q2 24 Earnings Conference Call At 9:00 AM ET |
| 25.07 13:47 | dpa-AFX: ROUNDUP: AbbVie Boosts FY24 Outlook |
| 25.07 13:42 | dpa-AFX: AbbVie Q2 Profit Decreases, But Beats Estimates |
| 25.07 13:42 | dpa-AFX: *ABBVIE Q2 ATTRIBUTABLE NET EARNINGS $1.37 BLN VS $2.02 BLN PRIOR YEAR |
| 25.07 13:41 | dpa-AFX: *ABBVIE RAISES FY ADJ. EPS GUIDANCE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
| 25.07 13:39 | dpa-AFX: *ABBVIE RAISES 2024 ADJ. EPS GUIDANCE RANGE FROM $10.61 - $10.81 TO $10.71 - $10.91 |
| 25.07 13:39 | dpa-AFX: *ABBVIE Q2 NET REVENUES OF $14.462 BLN, INCREASE OF 4.3% ON A REPORTED BASIS AND 5.6% ON OPERATIONAL BASIS |
| 25.07 13:38 | dpa-AFX: *ABBVIE Q2 EPS $0.77 ON A GAAP BASIS, A DECREASE OF 32.5% |
| 25.07 13:38 | dpa-AFX: *ABBVIE Q2 ADJ. EPS $2.65, DECREASE OF 8.9% |
| 12.07 14:48 | dpa-AFX: AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis |
| 12.07 14:33 | dpa-AFX: *ABBVIE SEEKS FDA AND EMA APPROVAL FOR UPADACITINIB IN GIANT CELL ARTERITIS |
| 10.07 14:45 | dpa-AFX: AbbVie Appoints Thakkar As EVP Of R&D, Chief Scientific Officer |
| 10.07 14:03 | dpa-AFX: *ABBVIE APPOINTS ROOPAL THAKKAR AS EVP, RESEARCH & DEVELOPMENT AND CHIEF SCIENTIFIC OFFICER |
| 01.07 14:17 | dpa-AFX: AbbVie's Robert Michael Assumes Role Of CEO |
| 01.07 14:02 | dpa-AFX: *ABBVIE SAYS ROBERT MICHAEL ASSUMED ROLE OF CEO |
| 28.06 08:14 | dpa-AFX: AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab |
|
|
